Vivani Medical Q3 net loss widens 11% year over year to $7.25 million

PUBT · 1d ago
Vivani Medical Q3 net loss widens 11% year over year to $7.25 million
  • Vivani Medical’s third-quarter 2026 net loss widened 11% year over year to $7.25 million.
  • Research and development expense rose 11% year over year to $5.02 million, primarily due to higher Biopharm clinical trial expenses.
  • Cash, cash equivalents and restricted cash fell 25% from June 30 to $15.5 million at September 30, 2026.
  • Top-line results from SLIM-1, the Phase 1 trial of its semaglutide implant for chronic weight management, are expected later this week.
  • The Cortigent-ClearOne merger awaits final regulatory approvals, with closing expected shortly after approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611111605PRIMZONEFULLFEED9875733) on November 11, 2026, and is solely responsible for the information contained therein.